Blueprint Historical Balance Sheet

BPMC Stock

USD 91.26 1.22 1.32%

Trend analysis of Blueprint Medicines Corp balance sheet accounts such as Short Long Term Debt Total of 166.4 M, Other Current Liabilities of 204.5 M or Total Current Liabilities of 273.8 M provides information on Blueprint Medicines' total assets, liabilities, and equity, which is the actual value of Blueprint Medicines Corp to its prevalent stockholders. By breaking down trends over time using Blueprint Medicines balance sheet statements, investors will see what precisely the company owns and what it owes to creditors or other parties at the end of each accounting year.

Cash Flow Balance Sheet Income Statement

Yuan Drop

Covid

Financial Statement Analysis is much more than just reviewing and examining Blueprint Medicines Corp latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Blueprint Medicines Corp is a good buy for the upcoming year.

Blueprint Medicines Inventory

14.29 Million

Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Blueprint Medicines Corp. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population.

About Blueprint Balance Sheet Analysis

Balance Sheet is a snapshot of the financial position of Blueprint Medicines Corp at a specified time, usually calculated after every quarter, six months, or one year. Blueprint Medicines Balance Sheet has two main parts: assets and liabilities. Liabilities are the debts or obligations of Blueprint Medicines and are divided into current liabilities and long term liabilities. An asset, on the other hand, is anything of value that can be converted into cash and which Blueprint currently owns. An asset can also be divided into two categories, current and non-current.

Blueprint Medicines Balance Sheet Chart

At present, Blueprint Medicines' Other Current Liabilities is projected to increase significantly based on the last few years of reporting. The current year's Total Current Liabilities is expected to grow to about 273.8 M, whereas Total Assets are forecasted to decline to about 827.6 M.

Total Assets Short Long Term Debt Total Total Current Liabilities Other Liab

Add Fundamental

Total Assets

Total assets refers to the total amount of Blueprint Medicines assets owned. Assets are items that have some economic value and are expended over time to create a benefit for the owner. These assets are usually recorded in Blueprint Medicines Corp books under different categories such as cash, marketable securities, accounts receivable,prepaid expenses, inventory, fixed assets, intangible assets, other assets, marketable securities, accounts receivable, prepaid expenses and others. The total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets.

Total Current Liabilities

Total Current Liabilities is an item on Blueprint Medicines balance sheet that include short term debt, accounts payable, accrued salaries payable, payroll taxes payable, accrued liabilities and other debts. Total Current Liabilities of Blueprint Medicines Corp are important to investors because some useful performance ratios such as Current Ratio and Quick Ratio require Total Current Liabilities to be accurate. The total amount of liabilities that a company is expected to pay within one year, including debts, accounts payable, and other short-term financial obligations.

Most accounts from Blueprint Medicines' balance sheet are interrelated and interconnected. However, analyzing balance sheet accounts one by one will only give a small insight into Blueprint Medicines Corp current financial condition. On the other hand, looking into the entire matrix of balance sheet accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Blueprint Medicines Corp. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population.

	2022	2023	2024	2025 (projected)
Short and Long Term Debt Total	562.7M	774.1M	126.1M	166.4M
Total Assets	1.3B	1.0B	1.2B	827.6M

Short Long Term Debt Total Total Assets

Blueprint Medicines balance sheet Correlations

	Total Assets	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Other Liab	Property Plant And Equipment Net	Current Deferred Revenue	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Other Assets	Long Term Debt	Cash And Short Term Investments	Common Stock Total Equity	Common Stock Shares Outstanding	Non Current Liabilities Total	Other Current Assets	Other Stockholder Equity	Total Liab	Property Plant And Equipment Gross	Total Current Assets	Short Term Debt
Total Assets		0.53	0.18	0.79	0.82	0.54	0.9	0.38	-0.07	-0.71	0.76	0.53	0.89	0.33	0.55	0.8	0.97	0.91	0.94	0.62	0.17	0.94	0.67	0.88	0.95	0.56
Short Long Term Debt Total	0.53		-0.15	0.63	0.07	0.7	0.65	0.52	0.67	-0.72	0.28	-0.09	0.28	0.13	-0.02	0.35	0.45	0.54	0.61	0.8	0.08	0.66	0.77	0.71	0.64	0.75
Other Current Liab	0.18	-0.15		0.4	0.19	0.18	0.21	-0.78	0.01	-0.33	0.55	0.11	0.31	0.55	0.11	0.13	0.11	0.25	0.26	0.15	0.17	0.25	0.21	0.21	0.06	0.43
Total Current Liabilities	0.79	0.63	0.4		0.41	0.9	0.83	0.26	0.33	-0.98	0.72	0.07	0.65	0.77	0.12	0.65	0.66	0.8	0.86	0.92	0.21	0.89	0.95	0.87	0.78	0.89
Total Stockholder Equity	0.82	0.07	0.19	0.41		0.06	0.62	0.15	-0.52	-0.26	0.62	0.76	0.85	0.06	0.76	0.71	0.91	0.67	0.66	0.12	0.14	0.62	0.2	0.53	0.7	0.1
Other Liab	0.54	0.7	0.18	0.9	0.06		0.59	0.37	0.49	-0.93	0.41	-0.13	0.31	0.78	-0.13	0.38	0.39	0.6	0.65	0.98	0.05	0.7	0.98	0.68	0.64	0.91
Property Plant And Equipment Net	0.9	0.65	0.21	0.83	0.62	0.59		0.37	0.24	-0.8	0.81	0.21	0.8	0.33	0.3	0.83	0.83	0.88	0.94	0.7	0.44	0.95	0.74	0.98	0.85	0.64
Current Deferred Revenue	0.38	0.52	-0.78	0.26	0.15	0.37	0.37		0.14	-0.3	-0.03	-0.03	0.17	-0.07	-0.01	0.37	0.38	0.3	0.33	0.42	-0.01	0.36	0.39	0.39	0.47	0.09
Net Debt	-0.07	0.67	0.01	0.33	-0.52	0.49	0.24	0.14		-0.48	0.02	-0.77	-0.15	0.17	-0.48	0.04	-0.21	0.02	0.13	0.54	0.09	0.19	0.49	0.33	-0.01	0.57
Retained Earnings	-0.71	-0.72	-0.33	-0.98	-0.26	-0.93	-0.8	-0.3	-0.48		-0.68	0.05	-0.53	-0.72	0.04	-0.59	-0.57	-0.77	-0.83	-0.96	-0.2	-0.87	-0.98	-0.87	-0.74	-0.92
Accounts Payable	0.76	0.28	0.55	0.72	0.62	0.41	0.81	-0.03	0.02	-0.68		0.29	0.78	0.44	0.15	0.67	0.68	0.83	0.83	0.46	0.28	0.83	0.54	0.81	0.65	0.52
Cash	0.53	-0.09	0.11	0.07	0.76	-0.13	0.21	-0.03	-0.77	0.05	0.29		0.45	-0.11	0.65	0.17	0.64	0.43	0.34	-0.11	-0.04	0.29	-0.06	0.13	0.51	-0.08
Non Current Assets Total	0.89	0.28	0.31	0.65	0.85	0.31	0.8	0.17	-0.15	-0.53	0.78	0.45		0.28	0.65	0.73	0.87	0.72	0.77	0.39	0.1	0.8	0.46	0.77	0.69	0.41
Non Currrent Assets Other	0.33	0.13	0.55	0.77	0.06	0.78	0.33	-0.07	0.17	-0.72	0.44	-0.11	0.28		-0.11	0.26	0.19	0.39	0.42	0.68	0.05	0.45	0.72	0.41	0.32	0.69
Other Assets	0.55	-0.02	0.11	0.12	0.76	-0.13	0.3	-0.01	-0.48	0.04	0.15	0.65	0.65	-0.11		0.38	0.64	0.28	0.29	-0.07	-0.02	0.29	-0.02	0.2	0.4	-0.02
Long Term Debt	0.8	0.35	0.13	0.65	0.71	0.38	0.83	0.37	0.04	-0.59	0.67	0.17	0.73	0.26	0.38		0.79	0.77	0.83	0.45	0.43	0.77	0.51	0.77	0.74	0.33
Cash And Short Term Investments	0.97	0.45	0.11	0.66	0.91	0.39	0.83	0.38	-0.21	-0.57	0.68	0.64	0.87	0.19	0.64	0.79		0.85	0.87	0.48	0.15	0.85	0.53	0.77	0.91	0.41
Common Stock Total Equity	0.91	0.54	0.25	0.8	0.67	0.6	0.88	0.3	0.02	-0.77	0.83	0.43	0.72	0.39	0.28	0.77	0.85		0.97	0.66	0.28	0.94	0.71	0.87	0.93	0.61
Common Stock Shares Outstanding	0.94	0.61	0.26	0.86	0.66	0.65	0.94	0.33	0.13	-0.83	0.83	0.34	0.77	0.42	0.29	0.83	0.87	0.97		0.72	0.29	0.98	0.77	0.94	0.94	0.67
Non Current Liabilities Total	0.62	0.8	0.15	0.92	0.12	0.98	0.7	0.42	0.54	-0.96	0.46	-0.11	0.39	0.68	-0.07	0.45	0.48	0.66	0.72		0.1	0.77	0.99	0.78	0.7	0.93
Other Current Assets	0.17	0.08	0.17	0.21	0.14	0.05	0.44	-0.01	0.09	-0.2	0.28	-0.04	0.1	0.05	-0.02	0.43	0.15	0.28	0.29	0.1		0.23	0.13	0.35	0.2	0.04
Other Stockholder Equity	0.94	0.66	0.25	0.89	0.62	0.7	0.95	0.36	0.19	-0.87	0.83	0.29	0.8	0.45	0.29	0.77	0.85	0.94	0.98	0.77	0.23		0.81	0.97	0.92	0.73
Total Liab	0.67	0.77	0.21	0.95	0.2	0.98	0.74	0.39	0.49	-0.98	0.54	-0.06	0.46	0.72	-0.02	0.51	0.53	0.71	0.77	0.99	0.13	0.81		0.81	0.73	0.93
Property Plant And Equipment Gross	0.88	0.71	0.21	0.87	0.53	0.68	0.98	0.39	0.33	-0.87	0.81	0.13	0.77	0.41	0.2	0.77	0.77	0.87	0.94	0.78	0.35	0.97	0.81		0.84	0.72
Total Current Assets	0.95	0.64	0.06	0.78	0.7	0.64	0.85	0.47	-0.01	-0.74	0.65	0.51	0.69	0.32	0.4	0.74	0.91	0.93	0.94	0.7	0.2	0.92	0.73	0.84		0.6
Short Term Debt	0.56	0.75	0.43	0.89	0.1	0.91	0.64	0.09	0.57	-0.92	0.52	-0.08	0.41	0.69	-0.02	0.33	0.41	0.61	0.67	0.93	0.04	0.73	0.93	0.72	0.6

Click cells to compare fundamentals

Blueprint Medicines Account Relationship Matchups

Blueprint Medicines balance sheet Accounts

	2020	2021	2022	2023	2024	2025 (projected)
Total Assets	1.7B	1.3B	1.3B	1.0B	1.2B	827.6M
Short Long Term Debt Total	89.6M	111.4M	562.7M	774.1M	126.1M	166.4M
Other Current Liab	98.0M	113.7M	(295.5M)	128.0M	194.7M	204.5M
Total Current Liabilities	130.8M	149.8M	183.2M	214.9M	260.8M	273.8M
Total Stockholder Equity	1.5B	970.7M	514.7M	130.6M	298.7M	484.3M
Other Liab	47.7M	35.8M	28.4M	437.0M	502.5M	527.6M
Property Plant And Equipment Net	101.7M	120.9M	115.2M	115.7M	100.8M	67.4M
Current Deferred Revenue	12.6M	36.6M	448.6M	812K	2.0M	1.9M
Net Debt	(595.0M)	(98.5M)	122.7M	702.8M	24.0M	25.2M
Retained Earnings	(631.4M)	(1.3B)	(1.8B)	(2.3B)	(2.4B)	(2.3B)
Accounts Payable	4.4M	8.3M	2.7M	4.7M	6.8M	4.2M
Cash	684.6M	209.9M	119.7M	71.3M	102.0M	96.9M
Non Current Assets Total	790.6M	698.2M	303.3M	240.9M	437.1M	257.2M
Non Currrent Assets Other	11.1M	19.8M	26.8M	40.9M	336.4M	353.2M
Other Assets	569.3M	19.8M	26.8M	1.0	1.15	1.09
Cash And Short Term Investments	1.5B	1.0B	1.1B	710.6M	615.5M	658.6M
Common Stock Total Equity	49K	58K	59K	60K	69K	41.4K
Common Stock Shares Outstanding	56.2M	58.5M	59.6M	60.6M	62.9M	45.8M
Liabilities And Stockholders Equity	1.7B	1.3B	1.3B	1.0B	1.2B	827.6M
Non Current Liabilities Total	117.5M	131.7M	652.0M	703.7M	620.4M	651.4M
Other Current Assets	22.0M	18.1M	35.0M	33.4M	36.0M	50.4M
Other Stockholder Equity	2.1B	2.3B	2.4B	2.5B	2.7B	1.5B
Total Liab	248.3M	281.5M	835.2M	918.6M	881.1M	925.2M
Property Plant And Equipment Gross	101.7M	146.3M	146.5M	154.1M	148.5M	80.5M
Total Current Assets	927.8M	554.0M	1.0B	808.4M	742.7M	570.5M
Accumulated Other Comprehensive Income	(5.2M)	(4.1M)	(10.4M)	(3.5M)	(3.6M)	(3.7M)
Short Term Debt	15.9M	16.2M	27.4M	81.4M	57.3M	60.1M
Common Stock	58K	59K	60K	61K	64K	45.9K
Property Plant Equipment	38.4M	34.1M	30.7M	33.3M	38.3M	22.7M
Net Tangible Assets	464.4M	1.5B	1.2B	514.7M	591.9M	613.2M
Net Receivables	25.3M	37.0M	36.9M	43.2M	77.6M	81.5M
Short Term Investments	187.2M	267.2M	825.3M	639.4M	513.5M	366.3M
Long Term Investments	677.9M	557.5M	133.5M	84.3M	277.1M	232.6M
Retained Earnings Total Equity	(945.2M)	(631.4M)	(1.3B)	(1.8B)	(1.6B)	(1.6B)
Capital Surpluse	1.4B	2.1B	2.3B	2.4B	2.7B	1.5B
Inventory	8.6M	21.8M	29.7M	21.2M	13.6M	14.3M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

CRM	Salesforce
C	Citigroup
GM	General Motors

When determining whether Blueprint Medicines Corp offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Blueprint Medicines' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Blueprint Medicines Corp Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Blueprint Medicines Corp Stock:

How To Invest In Blueprint

Details

Is Blueprint Stock a good investment?

Details

What is Blueprint Medicines' Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

You can also try the CEOs Directory module to screen CEOs from public companies around the world.

Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Blueprint Medicines. If investors know Blueprint will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Blueprint Medicines listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(1.07)

Revenue Per Share

8.095

Quarterly Revenue Growth

1.034

Return On Assets

(0.12)

Return On Equity

(0.31)

The market value of Blueprint Medicines Corp is measured differently than its book value, which is the value of Blueprint that is recorded on the company's balance sheet. Investors also form their own opinion of Blueprint Medicines' value that differs from its market value or its book value, called intrinsic value, which is Blueprint Medicines' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Blueprint Medicines' market value can be influenced by many factors that don't directly affect Blueprint Medicines' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Blueprint Medicines' value and its price as these two are different measures arrived at by different means. Investors typically determine if Blueprint Medicines is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Blueprint Medicines' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Blueprint Historical Balance Sheet

Blueprint Medicines Inventory

14.29 Million

About Blueprint Balance Sheet Analysis

Blueprint Medicines Balance Sheet Chart

Total Assets

Total Current Liabilities

Blueprint Medicines balance sheet Correlations

Blueprint Medicines Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Blueprint Medicines balance sheet Accounts

Also Currently Popular

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Total Liab	+ 0.99	Non Current Liabilities Total
Non Current Liabilities Total	+ 0.98	Other Liab
Total Liab	+ 0.98	Other Liab
Property Plant And Equipment Gross	+ 0.98	Property Plant And Equipment Net
Other Stockholder Equity	+ 0.98	Common Stock Shares Outstanding
Cash And Short Term Investments	+ 0.97	Total Assets

Total Liab	- 0.98	Retained Earnings
Retained Earnings	- 0.98	Total Current Liabilities
Non Current Liabilities Total	- 0.96	Retained Earnings
Retained Earnings	- 0.93	Other Liab
Short Term Debt	- 0.92	Retained Earnings
Property Plant And Equipment Gross	- 0.87	Retained Earnings